Lv1
88 积分 2023-05-17 加入
小核酸药物非临床特点和药理毒理评价策略
1个月前
已完结
The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem
3个月前
已完结
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38
5个月前
已完结
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
5个月前
已完结
Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD
5个月前
已完结
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
6个月前
已完结
皖公网安备34019202002308
